Low-Dose CT - Stage I Testicular Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

September 16, 2005

Primary Completion Date

October 14, 2011

Study Completion Date

September 30, 2028

Conditions
Testicular Cancer
Interventions
DIAGNOSTIC_TEST

Low-dose computed tomography (LDCT)

"In phase A of the study, patients will undergo conventional CT along with low dose CT. If patients have a normal conventional CT and a satisfactory low dose CT, they will move onto Phase B of the study in which they will undergo surveillance using low-dose CT. Three outcomes are possible with low-dose CT surveillance:~1. Normal LDCT:~ \- Patient continues on the study (i.e. continued surveillance)~2. Suspicious LDCT:~ \- Will undergo conventional CT and if results are normal, patient will continue on study. If conventional CT is abnormal, they will be taken off study~3. Elevated serum tumour markers or other evidence of metastatic disease:~ * Patient goes off study"

Trial Locations (1)

M5G 2M9

University Health Network, Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT03142802 - Low-Dose CT - Stage I Testicular Cancer | Biotech Hunter | Biotech Hunter